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E-mail: kawakami@med.kanazawa-u.ac.jpWe investigated the clinical value of methylation of long inter-
spersed nuclear element-1 (LINE-1) for the prognosis of colorectal
cancer (CRC) and for the survival benefit from adjuvant chemother-
apy with oral fluoropyrimidines. LINE-1 methylation in tumor DNA
was measured by quantitative methylation-specific PCR in 155
samples of stage II and stage III CRC. The presence of microsatellite
instability and CpG island methylator phenotype (CIMP) were
assessed and 131 microsatellite stable ⁄CIMP) cases were selected
for survival analysis, of which 77 patients had received postopera-
tive adjuvant chemotherapy with oral fluoropyrimidines. The CRC
cell lines were used to investigate possible mechanistic links
between LINE-1 methylation and effects of 5-fluorouracil (5-FU).
High LINE-1 methylation was a marker for better prognosis in
patients treated by surgery alone. Patients with low LINE-1 meth-
ylation who were treated with adjuvant chemotherapy survived
longer than those treated by surgery alone, suggestive of a sur-
vival benefit from the use of oral fluoropyrimidines. In contrast, a
survival benefit from chemotherapy was not observed for patients
with high LINE-1 methylation. The CRC cell lines treated with 5-FU
showed increased expression of LINE-1 mRNA. This was associated
with upregulation of the phospho-histone H2A.X in cells with low
LINE-1 methylation, but not in cells with high LINE-1 methylation.
The 5-FU-mediated induction of phospho-histone H2A.X, a marker
of DNA damage, was inhibited by knockdown of LINE-1. These
results suggest that LINE-1 methylation is a novel predictive mar-
ker for survival benefit from adjuvant chemotherapy with oral flu-
oropyrimidines in CRC patients. This finding could be important
for achieving personalized chemotherapy. (Cancer Sci 2011; 102:
166–174)
pigenetic alterations including CpG island hypermethylation
and global hypomethylation of DNA are commonly
observed in colorectal cancer (CRC).(1) The aberrant hyperme-
thylation of CpG islands is associated with distinctive clinical
features of CRC and shows promise as a diagnostic marker.(2,3)
Global hypomethylation, on the other hand, has attracted much
less attention and its clinical significance in cancer has not been
extensively investigated.
Long interspersed nuclear element-1 (LINE-1) is a non-long-
terminal-repeat class of retroposon that is the most successfully
integrated mobile element and accounts for approximately 18%
of the human genome.(4–6) The LINE-1 sequence is 6 kb in
length and contains a 5¢ untranslated region (UTR), two open
reading frames and a 3¢UTR. The 5¢UTR has internal promoterCancer Sci | January 2011 | vol. 102 | no. 1 | 166–174activity and the open reading frame encodes for nuclease and
reverse transcriptase activities that are necessary for transposi-
tion. Although the majority of retroposons no longer have the
ability to transpose due to mutations and deletions in their
sequence, approximately 100 full-length copies of LINE-1 in
the human genome retain this ability.(7,8) Because of the abun-
dance and functional ability of LINE-1, the level of its methyla-
tion is a surrogate of global gene methylation(9) and its
hypomethylation has been suggested to cause chromosomal
instability.
Hypomethylation of LINE-1 is predicted to be a factor for
unfavorable prognosis in CRC patients because of the associa-
tion between global hypomethylation and chromosomal instabil-
ity,(10) a known marker of poor prognosis.(11,12) Consistent with
this, our preliminary analysis of stage II and III CRC patients
who underwent curative surgery found that LINE-1 hypomethy-
lation was associated with a worse patient outcome.(13) Another
recent study also found that LINE-1 hypomethylation was inde-
pendently associated with shorter survival of colon cancer
patients.(14) However, these studies did not take into account the
use of postoperative adjuvant chemotherapy in their patient
cohorts and its possible influence on the observed prognostic
value of LINE-1 hypomethylation.
In this study, we investigated the prognostic value of LINE-1
methylation in stage II and III CRC patients who underwent
curative surgery and in whom the postoperative adjuvant che-
motherapy status was known. Our preliminary investigations
suggested that LINE-1 hypomethylation could be an indicator of
survival benefit from postoperative adjuvant chemotherapy with
oral fluoropyrimidines. However, this marker is associated with
the microsatellite instability (MSI) and CpG island methylator
(CIMP) phenotypes,(15,16) both of which have been implicated
in the response to 5-fluorouracil (5-FU).(2,17–19) To avoid a
possible confounding influence from these phenotypes, in the
present study we evaluated the prognostic and predictive signifi-
cance of LINE-1 methylation in a cohort of CRC patients with
microsatellite stable (MSS) and CIMP-negative (CIMP))
tumors.
Materials and Methods
Patients and specimens. The present study included 155
patients with stage II or III CRC who underwent surgery withdoi: 10.1111/j.1349-7006.2010.01776.x
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curative intent at Kanazawa University Hospital. The patients
comprised 90 males and 65 females and ranged in age from 33
to 93 years (mean, 65.6 years). The site of tumor was classified
as proximal or distal to the splenic flexure. A total of 49 patients
were thus defined as having proximal CRC and 106 with distal
CRC. Tumor stage was defined according to the International
Union Against Cancer (UICC) TNM system.(20) The postopera-
tive course of patients treated with and without adjuvant chemo-
therapy was retrospectively assessed by referring to their
medical records. In all, 94 patients received adjuvant chemother-
apy with oral fluoropyrimidines and 61 were treated with
surgery alone. None of the patients received pre-operative
radio-chemotherapy or postoperative radiation therapy. The oral
fluoropyrimidines used were 5-FU, UFT (a combination of tega-
fur and uracil), doxifluridine and carmofur in 14, 52, 17 and 11
patients, respectively. The median period of adjuvant chemo-
therapy use was 105 weeks (range, 21–275 weeks). The median
follow-up time was 58 months (range, 11–128 months) and 49
patients died of disease recurrence during the course of follow
up. Survival data for the 13 patients who died of other causes
was censored at the time of death.
Tissue samples for methylation analysis were obtained from
formalin-fixed and paraffin-embedded tumor blocks selected on
the basis of tumor cell content. The tumor tissue was dissected
manually from 10 lm paraffin sections. After deparaffinization
using xylene and ethanol, genomic DNA was extracted from the
tissue using QIAamp DNA mini kits (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. DNA samples from
adjacent normal tissues were prepared using the same method.
This project was approved by the Kanazawa University Medical
Ethics Committee.
Cell lines and culture conditions. The CRC cell lines SW48,
SW480, HCT116, HT-29, COLO205, LS411N and Caco-2 were
obtained from the American Type Culture Collection (Manas-
sas, VA, USA). Other cell lines were provided by Health Sci-
ence Research Resources Bank (Osaka, Japan). The cells were
maintained at 37C with 5% CO2 in Dulbecco’s modified Eagle
(SW48, SW480, SW837, HCT116, HT-29, Caco-2, CaR-1,
CCK81, LoVo) or RPMI 1640 (COLO205, CW2, DLD-1,
LS411N) medium supplemented with 10% fetal bovine serum
and antibiotics (100 units ⁄mL penicillin G and 100 lg ⁄mL
streptomycin; Gibco, Grand Island, NY, USA). Cells were
harvested during the exponential growth phase for extraction of
DNA, RNA and protein.
DNA methylation analysis. Genomic DNA extracted from tis-
sues and cultured cell lines was treated with bisulfite as
described previously.(21) Following the bisulfite treatment,
LINE-1 methylation was analyzed using a methylation-specific
real-time PCR assay as previously described.(22)
Methylation levels of CpG islands within promoter regions
were evaluated by MethyLight assay for the CIMP panel of
markers comprising CACNA1G, IGF2, NEUROG1, RUNX3
and SOCS1, where the percentage methylated reference (PMR)
values were derived using the ALU normalization control reac-
tion.(23) Simultaneous hypermethylation (PMR ‡ 10) of three or
more of these five markers was used to define a tumor as
CIMP+.
Microsatellite analysis for MSI and LOH. The MSI status was
determined using a three-marker panel of mononucleotide
repeats (BAT26, NR21 and NR27) reported to be highly sensi-
tive for the identification of MSI in CRC.(24) Primer sequences
and PCR conditions were described previously(25) and sense
primers were end-labeled with 6-carboxyfluorescein (BAT26
and NR-21) or VIC (NR-27). The PCR amplified fragments
were analyzed by capillary electrophoresis using the ABI-
PRISM 310 Sequence Detection System (Applied Biosystems,
Foster, CA, USA). GeneMapper software version 4.0 (Applied
Biosystems) was used to detect the fragment signal and estimateKawakami et al.the allelic size of each marker. Matched DNA samples from
tumor and adjacent normal tissues were analyzed in 139 cases,
and cases showing new alleles in the tumor DNA compared with
normal DNA were classified as having MSI. Microsatellite
instability was determined without reference to matching normal
DNA in 16 cases. For these cases, an allelic size difference of
>3 bp for BAT26 and >2 bp for the NR markers relative to the
quasi-monomorphic variation range was considered to represent
MSI, as described previously.(24) The quasi-monomorphic varia-
tion range of each marker was determined from investigation of
139 normal DNA samples. Tumors were classified as MSI if
they showed instability at one or more markers. The MSI status
of CRC cell lines was also determined using the quasi-mono-
morphic variation range and the three-marker panel described
above.
The LOH status was determined by screening three microsat-
ellite loci (D18S58, D18S61, D18S64) on chromosome 18q.
DNA samples from matched tumor and normal tissues were
amplified with sets of primers (Table S1) in which the forward
primer was labeled with 6-carboxyfluorescein. The PCR condi-
tions and determination of LOH were described previously.(26)
Tumors that showed LOH at one or more loci were classified as
LOH positive.
Northern blot analysis. The RNA probes to detect LINE-1
and b-actin mRNA were made by cloning into pGEM-T easy
Vector (Promega, Madison, WI, USA) of the RT-PCR fragment
of each gene from SW480 using M-MLV reverse transcriptase
(Invitrogen, Carlsbad, CA, USA), random hexamers and primers
listed in Table S1. This was followed by confirmation of the
sequence using BigDye Terminator Cycle Sequencing kit Ver-
sion 1.1 (Applied Biosystems). The RNA probes were synthe-
sized by SP6 RNA polymerase using the DIG Northern Starter
kit (Roche, Mannheim, Germany).
Total RNA was prepared by the single-step guanidinium iso-
thiocyanate method using ISOGEN (Nippon Gene, Toyama,
Japan). Polyadenylated (polyA) RNA was then purified using
oligotex-dT30 (TaKaRa Bio, Otsu, Japan). Total RNA (50 lg)
was denatured for 5 min at 65C in a mixture of 200 lL binding
buffer (10 mM Tris–HCl at pH 8.0, 1 mM EDTA, 0.1% SDS)
and 15 lL of oligotex-dT30 followed by the addition of 40 lL
of 5 M NaCl and incubation for 10 min at 37C. The solution
was centrifuged at 18 000g for 3 min. The pellet of oligotex-
dT30-binding polyA RNA was washed in 1 mL buffer (10 mM
Tris–HCl at pH 8.0, 1 mM EDTA, 0.1% SDS, 0.5 M NaCl) and
then centrifuged at 18 000g for 3 min. The pellet was suspended
in 200 lL TE (10 mM Tris–HCl at pH 8.0, 1 mM EDTA) and
denatured for 5 min at 65C followed by rapid chilling on ice
and centrifugation at 18 000g for 3 min. The supernatants were
collected and polyA RNA was precipitated in 440 lL of ethanol
containing 20 lL of 3 M sodium acetate and 20 lg of glycogen.
After centrifugation at 18 000g for 15 min at 4C, the precipi-
tated RNA was washed with 70% ethanol, air dried and sus-
pended in 10 lL of nuclease-free water.
Purified polyA RNA was electrophoresed in formaldehyde-
denatured 1% agarose gels and blotted onto Hybond N+ (Amer-
sham, Little Chalfont, Buckinghamshire, UK). The blotted
membrane was prehybridized in DIG Easy Hyb buffer (Roche)
at 68C for 30 min. Heat-denatured LINE-1 probe (95C for
5 min) was then added to fresh DIG Easy Hyb buffer and incu-
bated with the membrane in a plastic bag at 68C overnight. The
hybridized probe signal was developed using DIG Wash and
Block Buffer Set (Roche), alkaline phosphatase-labeled anti-
DIG antibody (Roche) and CDP-Star (New England BioLabs,
Beverly, MA, USA) following the manufacturer’s protocol. The
b-actin probe was used as an internal control.
Western blot analysis. Histone proteins were extracted from
cultured cells using EpiQuik Total Histone Extraction kit
(Epigentek, Brooklyn, NY, USA) following the manufacturer’sCancer Sci | January 2011 | vol. 102 | no. 1 | 167
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Table 1. Association between the LINE-1 methylation level and
clinicopathological features
n LINE-1 methylation P-value
Age (years)
>66 73 84.3 (78.5–88.1) 0.91
£66 82 84.7 (78.7–88.5)
Gender
Male 90 85.4 (79.2–89.0) 0.18
Female 65 82.9 (76.5–88.0)
Site
Proximal 49 86.7 (81.6–89.8) 0.041
Distal 106 84.1 (77.3–87.7)
Stage
II 80 84.0 (77.3–88.1) 0.23
III 75 85.8 (81.2–88.7)
Histology
Well 71 85.3 (79.3–88.9) 0.020
Moderately 67 82.3 (76.1–86.5)
Poorly 10 88.1 (86.4–91.1)
Mucinous 7 87.0 (80.4–89.3)
MSI
MSI 15 88.1 (85.7–90.6) 0.0085
MSS 140 84.3 (78.1–88.2)
CIMP
+ 18 87.5 (82.2–89.6) 0.053
) 137 84.3 (77.3–88.4)
LINE-1 methylation levels are shown as the median (25th–75th
percentile). Histology of adenocarcinoma was sub-classified into well-,
moderately- and poorly-differentiated adenocarcinoma according to
their grading. CIMP, CpG island methylator phenotype; LINE-1, long
interspersed nuclear element-1; MSI, microsatellite instability; MSS,
microsatellite stable; mucinous, mucinous adenocarcinoma; n, number
of patients.protocol. A 10 lg aliquot of histone protein extract was sepa-
rated in 12% NuPAGE Novex Bis–Tris gel (Invitrogen), electro-
transferred to a nitrocellulose membrane and analyzed by
western immunoblotting for the proteins of interest. Primary anti-
bodies to phospho-histone H2A.XSer139 and total histone H2A.X
were obtained from Upstate Biotechnology (Lake Placid, NY,
USA) and used at dilutions of 1:2000 and 1:3000, respectively.
Signals were developed using enhanced chemiluminescence
(ECL; Amersham). Immunoblotting signals were measured by
the CS analyzer version 2.0 (ATTO, Tokyo, Japan).
RNA interference. Small interfering RNA (siRNA) specific to
the LINE-1 sequence and non-specific siRNA were synthesized
by Nippon EGT (Toyama, Japan); the sequences are listed in
Table S1. The SW480 cells were transiently transfected with 2.5
nM of LINE-1 siRNA or non-specfic siRNA using Lipofecta-
mine RNAiMAX (Invitrogen) according to the manufacturer’s
instructions. At 24 h after transfection with the respective
siRNA, the cells were treated with DMSO or 5-FU for 6 days
and then harvested for examination.
Statistical analysis. The level of LINE-1 methylation was
expressed as a median value (25th–75th percentile). The Mann–
Whitney U-test or the Kruskal–Wallis test was used to compare
the LINE-1 methylation levels between two or three variables,
respectively. Kaplan–Meier analysis and the log-rank test were
used to evaluate differences in survival between patient groups.
Clinicopathological characteristics of the respective patient
groups were compared by Mann–Whitney U-test for age and
Chi-squared test for other variables. The prognostic significance
of multiple variables was evaluated using the Cox proportional
hazard regression model. Correlation between LINE-1 methyla-
tion and mRNA expression level was analyzed by Spearman’s
rank test. All P-values shown are two tailed with P < 0.05 taken
as statistically significant. Statistical analyses were carried out
using the R software package version 2.7.2.(27)
Results
LINE-1 hypomethylation is an independent factor for poor
prognosis in CRC and is associated with LOH on chromosome
18q. The median level of LINE-1 methylation in primary
tumors as determined by quantitative methylation-specific PCR
was 84.7% (range, 27.8–94.0%). The LINE-1 methylation was
significantly higher in proximal colon tumors compared with
those arising in the distal colon and rectum (Table 1). Moder-
ately differentiated adenocarcinomas showed less LINE-1 meth-
ylation than tumors with other histological subtypes (well- and
poorly-differentiated adenocarcinoma, mucinous carcinoma).
Consistent with previous reports,(15,16) LINE-1 methylation was
higher in tumors that were MSI (P = 0.0085) or CIMP+
(P = 0.053).
In order to investigate the prognostic significance of LINE-1
methylation independently of MSI and CIMP status, survival
analyses were performed on 131 CRC patients whose tumors
were MSS and CIMP) according to the criteria described in the
Materials and Methods. The median LINE-1 methylation level
in tumor DNA from these patients was 84.3% and no association
was observed with the site of tumor origin (Table S2). The
LINE-1 methylation level was significantly lower in tumor com-
pared with adjacent normal tissue (P < 0.0001, Fig. 1). Patients
who received adjuvant chemotherapy showed better outcome
compared with those treated by surgery alone (P = 0.024,
Fig. 2a), suggesting a positive influence of postoperative therapy
on patient prognosis.
The LINE-1 methylation level of tumors was classified as
high or low relative to the median value of 84.3%. This value is
<10 percentile (85.6%) in the distribution of LINE-1 methyla-
tion of normal tissues (Fig. 1). High LINE-1 methylation was
associated with a trend for longer survival in the overall patient168group (P = 0.055, Fig. 2b). This reached statistical significance
in patients treated by surgery alone (P = 0.018, Fig. 2c) and
multivariate analysis revealed it to be an independent marker of
good prognosis in such patients (P = 0.022, Table 2). Consistent
with this observation, high LINE-1 methylation was not associ-
ated with any of the standard clinicopathological features in
patients treated by surgery alone (Table S3). High LINE-1
methylation showed no prognostic significance in patients who
received adjuvant chemotherapy (Fig. 2d). A trend of associa-
tion between good prognosis and high LINE-1 methylation level
in the patients treated by surgery alone but not in those who
received adjuvant chemotherapy was also observed when the
LINE-1 level was classified into low (1–33 percentile), medium
(34–66 percentile) and high (67–100 percentile; Fig. S1).
To test for possible association between LINE-1 hypomethy-
lation and genetic abnormality in our CRC cases, we analyzed
the LOH status of chromosome 18q by microsatellite analysis
and capillary electrophoresis in 37 randomly selected
MSS ⁄CIMP) cases. LINE-1 methylation was significantly
lower in tumors with 18q LOH compared with those without
LOH (Fig. S2). This observation is consistent with a previous
report showing the link between LINE-1 hypomethylation and
chromosomal instability in CRC.(28)
LINE-1 hypomethylation is a potential biomarker for the
prediction of response to oral fluoropyrimidines in CRC. The
survival benefit from adjuvant chemotherapy with oral fluoro-
pyrimidines was assessed in patient sub-groups stratified accord-
ing to the median value of LINE-1 methylation level. Patients
with low LINE-1 methylation who received adjuvant chemo-
therapy lived significantly longer than those treated by surgery
alone (P = 0.0079, Fig. 3a). In contrast, patients with high
LINE-1 methylation showed no difference in survival betweendoi: 10.1111/j.1349-7006.2010.01776.x
ª 2010 Japanese Cancer Association
Fig. 1. Distribution of the long interspersed nuclear element-1 (LINE-
1) methylation level in normal and tumor tissues. The LINE-1
methylation is significantly lower in tumor compared with normal




(d)those treated with or without adjuvant chemotherapy (P = 0.68,
Fig. 3b). When the LINE-1 level was classified into low (1–33
percentile), medium (34–66 percentile) and high (67–100 per-
centile), the patients who received adjuvant chemotherapy
showed better survival in the low (P = 0.030) and medium
(P = 0.068) but not in the high (P = 0.98) LINE-1 methylation
group (Fig. S3). These results suggest that low levels of LINE-1
methylation are predictive of response to oral fluoropyrimidines,
but not high levels.
The clinicopathological features of the four patient subgroups
shown in Figure 3 are outlined in Table S4. In both the high and
low methylation groups, patients who received adjuvant chemo-
therapy were significantly younger than those who did not.
While this could potentially account for the survival difference
observed between treatment groups, it does not explain why
only patients with low LINE-1 methylation appeared to benefit
from adjuvant chemotherapy (Fig. 3). Apart from age, no other
significant differences in clinicopathological characteristicsFig. 2. Kaplan–Meier survival analysis of patient groups stratified
according to use of postoperative adjuvant chemotherapy (a) and ⁄ or
long interspersed nuclear element-1 (LINE-1) methylation (b–d). The
prognosis of LINE-1 low group (dashed line) and those of LINE-1 high
group (solid line) were compared in the overall MSS ⁄ CIMP) cohort (b)
and in patients treated by surgery alone (c) or with adjuvant
chemotherapy (d). The log-rank test was used for each comparison
and P-values are shown. CIMP, CpG island methylator phenotype;
MSS, microsatellite stable. tx, chemotherapy.
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Table 2. Multivariate analysis for the prognostic significance of
clinicopathological factors and LINE-1 methylation in MSS ⁄ CIMP- CRC
treated with surgery alone
Variables n Hazard ratio (95% CI) P-value
Age (years)
>66 40 1.00 0.10
£66 14 0.41 (0.14–1.19)
Gender
Male 29 1.00 0.46
Female 25 0.72 (0.30–1.72)
Site
Proximal 14 1.00 0.56
Distal 40 1.41 (0.44–4.55)
Stage
II 30 1.00 0.77
III 24 0.88 (0.37–2.11)
Histology
Others 28 1.00 0.10
Well 26 0.44 (0.16–1.19)
LINE-1 methylation
High 26 1.00 0.022
Low 28 3.02 (1.17–7.80)
Histology of adenocarcinoma was sub-classified into well-,
moderately- and poorly-differentiated adenocarcinoma according to
their grading. Cases of moderately- (n = 26) and poorly-differentiated
adenocarcinoma (n = 1) and mucinous adenocarcinoma (n = 1) were
combined for the analysis. CI, confidence interval; CIMP, CpG island
methylator phenotype; CRC, colorectal cancer; LINE-1, long




Fig. 3. Kaplan–Meier survival analysis of patients stratified according
to the use of postoperative adjuvant chemotherapy in patients with
low long interspersed nuclear element-1 (LINE-1) methylation (a) and
in patients with high LINE-1 methylation (b). Solid lines indicate
patients treated with surgery alone and dashed lines indicate patients
treated with adjuvant chemotherapy. The log-rank test was used for
each comparison and P-values are shown. tx, chemotherapy.were apparent between patients treated with or without adjuvant
chemotherapy. Multivariate analysis revealed that adjuvant che-
motherapy was an independent prognostic factor for better sur-
vival in patients with low LINE-1 methylation, but not in
patients with high LINE-1 methylation (Table 3). These results
suggest that LINE-1 hypomethylation is a potential biomarker
for the response of CRC patients to oral fluoropyrimidines in the
adjuvant setting.
5-FU increases LINE-1 mRNA expression and induces DNA
damage in CRC cells with LINE-1 hypomethylation. In vitro stud-
ies were performed to investigate the possible mechanism by
which LINE-1 hypomethylation was associated with a good
clinical response to oral fluoropyrimidines. Of the 13 CRC cell
lines screened for MSI and CIMP status, three (SW480, Caco-2,
CaR-1) were found to be MSS ⁄CIMP) (Fig. 4a). The relation-
ship between LINE-1 methylation and expression of its full-
length transcript was examined by northern blot analysis in these
MSS ⁄CIMP) cell lines and in HT-29, HCT116 and SW48 cells
(Fig. 4b). LINE-1 mRNA was detected as a single band of
approximately 6 kb in size, representing its known full-length
transcript (Fig. 4b, upper panel). The LINE-1 methylation level
was inversely correlated with the expression of its full-length
mRNA (Fig. 4b, lower panel).
Since LINE-1 mRNA was highly expressed in CRC cells
with LINE-1 hypomethylation, we hypothesized that it may
play a role in the therapeutic effect of 5-FU. To investigate this
hypothesis, we looked for changes in the expression of LINE-1
mRNA in CRC cells following treatment with 5-FU. The 5-FU
treatment had the effect of increasing LINE-1 mRNA expres-
sion in all three MSS ⁄CIMP) cell lines, although the baseline
expression level of the LINE-1 mRNA was less in CaR-1 cells
than SW480 and Caco-2 cells (Fig. 4c, upper panels). The
LINE-1 sequence contains an open reading frame that encodes
a protein with nuclease activity,(29) suggesting that increased
LINE-1 expression may be responsible for the DNA double170strand breaks (DSB) observed in cells following treatment with
5-FU. To test this possibility, the phosphorylation of histone
H2A.X at serine 139 (p-histone H2A.XSer139) was analyzed by
western immunoblotting. Phospho-histone H2A.XSer139 is a
well-established marker of DSB(30) and have been used to
assess the effect of 5-FU.(31,32) In SW480 and Caco-2 cells, the
level of p-histone H2A.XSer139 increased in parallel with the
upregulation of LINE-1 mRNA after 5-FU treatment (Fig. 4c,
lower panels). In contrast, the level of p-histone H2A.XSer139
showed no change in CaR-1 cells following 5-FU treatment.
The CaR-1 cells express less LINE-1 mRNA and have more
LINE-1 methylation compared with SW480 and Caco-2 cells
(Fig. 4b,c).
To further investigate whether increased LINE-1 expression
is responsible for DNA damage following 5-FU treatment, RNA
interference was used to deplete LINE-1 prior to treatment of
the SW480 cells. When the cells were pretreated with non-spe-
cific control siRNA, p-histone H2A.XSer139 expression was sig-
nificantly induced following 5-FU treatment. However, when
cells were pretreated with LINE-1-specific siRNA this induction
of p-histone H2A.XSer139 by 5-FU was suppressed (Fig. 4d).
These results suggest that in CRC cells with low LINE-1
methylation, augmented high expression of LINE-1 mRNA by
5-FU subsequently leads to an increase in DSB and eventually
to cell death. 5-FU may be ineffective in cells with high LINE-1doi: 10.1111/j.1349-7006.2010.01776.x
ª 2010 Japanese Cancer Association
Table 3. Multivariate analysis for the prognostic significance of clinicopathological factors and postoperative therapy in MSS ⁄ CIMP) CRC with
a low LINE-1 methylation level and in those with a high LINE-1 methylation level
Variables
Low LINE-1 methylation High LINE-1 methylation
n Hazard ratio (95% CI) P-value n Hazard ratio (95% CI) P-value
Age (years)
>66 33 1.00 0.21 29 1.00 0.67
£66 33 0.60 (0.27–1.34) 36 1.29 (0.40–4.16)
Gender
Male 34 1.00 0.49 46 1.00 0.58
Female 32 0.76 (0.35–1.67) 19 0.67 (0.16–2.78)
Site
Proximal 16 1.00 0.42 17 1.00 0.058
Distal 50 1.52 (0.56–4.00) 48 5.88 (0.94–33.3)
Stage
II 37 1.00 0.32 34 1.00 0.023
III 29 1.48 (0.67–3.20) 31 4.19 (1.22–14.4)
Histology
Others 38 1.00 0.48 28 1.00 0.14
Well 28 0.75 (0.33–1.68) 37 2.61 (0.74–9.26)
Adjuvant therapy
Surgery alone 28 1.00 0.021 26 1.00 0.27
Chemotherapy 38 0.38 (0.17–0.87) 39 0.49 (0.14–1.74)
Histology of adenocarcinoma was sub-classified into well-, moderately- and poorly-differentiated adenocarcinoma according to their grading.
Cases of moderately- and poorly-differentiated adenocarcinoma and mucinous adenocarcinoma were combined for the analysis in the low LINE-
1 methylation group (n = 35, 1 and 2, respectively) and in the high LINE-1 methylation group (n = 23, 4 and 1, respectively). CI, confidence
interval; LINE-1, long interspersed nuclear element-1; n, number of patients.methylation because the low baseline expression of LINE-1
mRNA in these cells is insufficient to increase DSB.
Discussion
In the present study, we explored the prognostic and predictive
significance of LINE-1 methylation in CRC with the
MSS ⁄CIMP) phenotype. The MSI phenotype has been studied
extensively in CRC and is associated with a good prognosis.(33)
In addition, several studies have shown that CRC patients with
an MSS ⁄CIMP+ tumor phenotype have a worse survival com-
pared with those with the MSS ⁄CIMP) phenotype.(34–36) LINE-
1 methylation was shown in the present (Table 1) and previous
studies(15,16) to be associated with both the MSI and CIMP phe-
notypes. Because this could complicate the interpretation of sur-
vival data for LINE-1 methylation, we restricted the current
study to MSS ⁄CIMP) CRC.
Consistent with a previous study on a large CRC cohort,(14)
patients with low LINE-1 methylation had shorter survival than
those with high LINE-1 methylation (Fig. 2b). However, the
present study also included information on postoperative adju-
vant chemotherapy and analysis of this data showed that the
prognostic significance of LINE-1 hypomethylation was
restricted to patients treated by surgery alone (Fig. 2c,d). This
result demonstrates that LINE-1 hypomethylation is a marker of
poor prognosis in non-adjuvant treated CRC patients indepen-
dently of the MSI and CIMP+ phenotypes. The association
between LINE-1 hypomethylation and poor prognosis in CRC is
not surprising because previous reports demonstrated that LOH-
positive CRC has a lower LINE-1 methylation level(28) and the
LOH on chromosome 18q is a poor prognostic marker.(11,37) To
test whether the LINE-1 methylation level measured by our
method is indeed associated with the 18q LOH we analyzed three
microsatellite locus on chromosome 18q. The result showed that
the LINE-1 methylation level was significantly lower in tumors
with 18q LOH compared with those without LOH, suggesting
links between LINE-1 hypomethylation, LOH on 18q and poor
prognosis in CRC. These results warrant further study of LINE-1Kawakami et al.methylation as a potentially useful prognostic marker for predict-
ing the clinical course of early stage CRC patients.
The major and unexpected finding from this study was the
predictive value of LINE-1 hypomethylation for survival benefit
from chemotherapy with oral fluoropyrimidines in CRC patients
(Fig. 3a). This was not apparent for patients with high LINE-1
methylation levels (Fig. 3b). A previous clinical trial has dem-
onstrated that CRC patients with stage III disease who under-
went a curative operation obtain a survival benefit from
adjuvant chemotherapy with 5-FU-based regimens.(38) However,
adjuvant chemotherapy is not effective for all patients and a sub-
stantial number suffer from disease recurrence and ⁄or unpredict-
able serious adverse effects. Many strategies have therefore
been explored to achieve optimal selection of patients who will
benefit from adjuvant chemotherapy.(39) Although a number of
candidate markers that predict survival benefit from adjuvant
chemotherapy with 5-FU-based regimens have been pro-
posed,(18,40,41) to date none have been validated in prospective
trials or introduced into clinical practice. Our results suggest the
LINE-1 methylation level in tumor DNA is a promising predic-
tive marker for benefit from adjuvant treatment with oral fluoro-
pyrimidines after curative surgery of CRC. Orally bioavailable
fluoropyrimidines can improve the quality of life for cancer
patients compared with intravenous administration of 5-FU.(42)
The LINE-1 methylation marker in CRC could potentially opti-
mize the clinical use of oral fluoropyrimidines and improve
patient quality of life. Prospective randomized studies are
required to clarify the clinical significance of LINE-1 methyla-
tion status as a predictive factor for response to adjuvant chemo-
therapy with oral fluoropyrimidines in CRC.
Our observation of an apparent survival benefit from oral flu-
oropyrimidines in patients with low tumor levels of LINE-1
methylation was supported by mechanistic studies linking
LINE-1 methylation, 5-FU treatment and DNA damage in CRC
cells. We observed a close relationship between the levels of
LINE-1 methylation and full-length LINE-1 mRNA expression
in CRC cells (Fig. 4b). This observation led us to hypothesize
that cells with low LINE-1 methylation had a greater potentialCancer Sci | January 2011 | vol. 102 | no. 1 | 171





Fig. 4. In vitro mechanistic studies linking long interspersed nuclear element-1 (LINE-1) methylation, 5-fluorouracil (5-FU) treatment and DNA
damage in colorectal cancer (CRC) cells. (a) Results for 13 CRC cell lines screened for microsatellite instability (MSI), CpG island methylator
phenotype (CIMP) and LINE-1 methylation level. The methylation status of five CIMP-defining CpG island markers was determined by MethyLight
assay in which a reading of the percentage of methylated reference (PMR) ‡10 was defined as hypermethylated (black boxes). White boxes
indicate PMR <10. (b) The relationship between the LINE-1 methylation level and expression of LINE-1 mRNA. Northern blot analysis of full-
length LINE-1 mRNA and b-actin expression is shown in the upper panel. The LINE-1 methylation level correlated inversely with the relative
amount of LINE-1 mRNA quantified by densitometry and normalized to b-actin with statistical significance (Spearman’s q = )0.94, P = 0.017,
lower panel). (c) Microsatellite stable (MSS) ⁄ CIMP) cells were treated with the indicated 5-FU concentration for 6 days followed by cell
harvesting to isolate RNA and histone protein. LINE-1 and b-actin mRNA were detected by northern blot analysis and are shown in the upper
panel with numbers reflecting the relative amount of LINE-1 mRNA quantified by densitometry and normalized to b-actin. Phospho-histone
H2A.XSer139 (p-H2A.X) and total histone H2A.X (H2A.X) proteins were detected by western blot analysis and are shown in the lower panel with
numbers reflecting the relative amount of p-H2A.X protein normalized to H2A.X. (d) SW480 cells were transfected with either non-specific (NC
siRNA) or LINE-1-specific siRNA (LINE-1 siRNA) followed by treatment with either DMSO or 5-FU (2 lM) for 6 days. The expression of p-H2A.X
and H2A.X was quantified using densitometry and the relative expression of p-H2A.X to H2A.X (p-H2A.X ⁄H2A.X) is shown in the bar graph at
the bottom of the panel. The SW480 cells treated with non-specific siRNA and DMSO was set as 1. Values shown are the mean and the error
bars represent standard deviation from three separate experiments. The asterisk indicates statistical significance (P < 0.05) for comparison of
DMSO and 5-FU-treated cells in the same experimental conditions for transfected siRNA.to undergo DSB following 5-FU treatment because the full-
length LINE-1 mRNA encodes for a protein with nuclease activ-
ity.(29) Our in vitro study demonstrated that 5-FU treatment
increases the expression of LINE-1 mRNA in MSS ⁄CIMP)
CRC cells (Fig. 4c). This was paralleled by increased DNA
damage (assessed by p-histone H2A.XSer139 expression) in
SW480 and Caco-2 cells with low LINE-1 methylation (54%
and 57%), but not in CaR-1 cells with high LINE-1 methylation
(72%). Therefore, the increase in LINE-1 expression may be
causally linked to 5-FU-induced DNA damage in cases where
tumor cells have low LINE-1 methylation and express high
baseline levels of LINE-1 mRNA (in case of SW480 and Caco-
2). A causal link between increased LINE-1 mRNA and DNA
damage induced by 5-FU treatment was further suggested by
knockdown experiments of LINE-1 expression (Fig. 4d). These
results could explain why tumors with LINE-1 hypomethylation
appear to be responsive to adjuvant chemotherapy using oral flu-
oropyrimidines. On the other hand, we postulate that 5-FU may172be ineffective in CRC cells with high LINE-1 methylation
because their low baseline expression of LINE-1 mRNA is
insufficient to induce DSB following 5-FU treatment (in case of
CaR-1). This mechanism could explain our observation that
CRC patients whose tumors show high LINE-1 methylation
respond poorly to oral fluoropyrimidines (Fig. 3b). Our in vitro
results suggest that further studies on the possible links between
LINE-1 hypomethylation, LINE-1 expression, nuclease activity,
DSB formation and sensitivity to 5-FU may lead to novel strate-
gies for improving the cytotoxic effect of 5-FU.
In conclusion, we found that LINE-1 hypomethylation in
MSS ⁄CIMP) CRC had predictive value for benefit from adju-
vant chemotherapy with oral fluoropyrimidines. Our in vitro
studies have suggested a possible underlying mechanism for the
link between LINE-1 hypomethylation in CRC cells and their
susceptibility to fluoropyrimidines. These observations could
have important implications for the future development of per-
sonalized chemotherapy and novel 5-FU-based regimens.doi: 10.1111/j.1349-7006.2010.01776.x
ª 2010 Japanese Cancer Association
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